Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Arsenic exposure predicts bladder cancer survival in a US population.

Kwong RC, Karagas MR, Kelsey KT, Mason RA, Tanyos SA, Schned AR, Marsit CJ, Andrew AS.

World J Urol. 2010 Aug;28(4):487-92. doi: 10.1007/s00345-009-0477-y. Epub 2009 Oct 16.

2.

Arsenic concentrations in prediagnostic toenails and the risk of bladder cancer in a cohort study of male smokers.

Michaud DS, Wright ME, Cantor KP, Taylor PR, Virtamo J, Albanes D.

Am J Epidemiol. 2004 Nov 1;160(9):853-9.

PMID:
15496537
3.

Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study.

Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, Greenberg ER.

Am J Epidemiol. 2001 Mar 15;153(6):559-65.

PMID:
11257063
4.

Diet and toenail arsenic concentrations in a New Hampshire population with arsenic-containing water.

Cottingham KL, Karimi R, Gruber JF, Zens MS, Sayarath V, Folt CL, Punshon T, Morris JS, Karagas MR.

Nutr J. 2013 Nov 16;12:149. doi: 10.1186/1475-2891-12-149.

5.

Assessment of cancer risk and environmental levels of arsenic in New Hampshire.

Karagas MR, Stukel TA, Tosteson TD.

Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94.

PMID:
12018020
6.

Incidence of transitional cell carcinoma of the bladder and arsenic exposure in New Hampshire.

Karagas MR, Tosteson TD, Morris JS, Demidenko E, Mott LA, Heaney J, Schned A.

Cancer Causes Control. 2004 Jun;15(5):465-72.

PMID:
15286466
7.

Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population.

Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B.

Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50.

8.

Intra-individual variability in toenail arsenic concentrations in a Michigan population, USA.

Slotnick MJ, Meliker JR, Nriagu JO.

J Expo Sci Environ Epidemiol. 2008 Mar;18(2):149-57. Epub 2007 Apr 11.

PMID:
17426735
9.

Lifetime exposure to arsenic in drinking water and bladder cancer: a population-based case-control study in Michigan, USA.

Meliker JR, Slotnick MJ, AvRuskin GA, Schottenfeld D, Jacquez GM, Wilson ML, Goovaerts P, Franzblau A, Nriagu JO.

Cancer Causes Control. 2010 May;21(5):745-57. doi: 10.1007/s10552-010-9503-z. Epub 2010 Jan 19.

10.

Lung cancer in a U.S. population with low to moderate arsenic exposure.

Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ.

Environ Health Perspect. 2009 Nov;117(11):1718-23. doi: 10.1289/ehp.0900566. Epub 2009 Jul 2.

11.

Elevated Bladder Cancer in Northern New England: The Role of Drinking Water and Arsenic.

Baris D, Waddell R, Beane Freeman LE, Schwenn M, Colt JS, Ayotte JD, Ward MH, Nuckols J, Schned A, Jackson B, Clerkin C, Rothman N, Moore LE, Taylor A, Robinson G, Hosain GM, Armenti KR, McCoy R, Samanic C, Hoover RN, Fraumeni JF Jr, Johnson A, Karagas MR, Silverman DT.

J Natl Cancer Inst. 2016 May 2;108(9). pii: djw099. doi: 10.1093/jnci/djw099. Print 2016 Sep.

12.

Associations between toenail arsenic concentration and dietary factors in a New Hampshire population.

Gruber JF, Karagas MR, Gilbert-Diamond D, Bagley PJ, Zens MS, Sayarath V, Punshon T, Morris JS, Cottingham KL.

Nutr J. 2012 Jun 29;11:45. doi: 10.1186/1475-2891-11-45.

13.

Decreased DNA repair gene expression among individuals exposed to arsenic in United States drinking water.

Andrew AS, Karagas MR, Hamilton JW.

Int J Cancer. 2003 Apr 10;104(3):263-8.

14.

Case-control study of bladder cancer and exposure to arsenic in Argentina.

Bates MN, Rey OA, Biggs ML, Hopenhayn C, Moore LE, Kalman D, Steinmaus C, Smith AH.

Am J Epidemiol. 2004 Feb 15;159(4):381-9.

PMID:
14769642
15.

Risk of death from cardiovascular disease associated with low-level arsenic exposure among long-term smokers in a US population-based study.

Farzan SF, Chen Y, Rees JR, Zens MS, Karagas MR.

Toxicol Appl Pharmacol. 2015 Sep 1;287(2):93-97. doi: 10.1016/j.taap.2015.05.013. Epub 2015 Jun 3.

16.

Markers of low level arsenic exposure for evaluating human cancer risks in a US population.

Karagas MR, Le CX, Morris S, Blum J, Lu X, Spate V, Carey M, Stannard V, Klaue B, Tosteson TD.

Int J Occup Med Environ Health. 2001;14(2):171-5.

PMID:
11548067
17.

DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk.

Andrew AS, Mason RA, Kelsey KT, Schned AR, Marsit CJ, Nelson HH, Karagas MR.

Toxicol Lett. 2009 May 22;187(1):10-4. doi: 10.1016/j.toxlet.2009.01.013. Epub 2009 Jan 20.

18.

Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations.

Karagas MR, Tosteson TD, Blum J, Klaue B, Weiss JE, Stannard V, Spate V, Morris JS.

Am J Epidemiol. 2000 Jul 1;152(1):84-90.

PMID:
10901333
19.

Estimating water supply arsenic levels in the New England Bladder Cancer Study.

Nuckols JR, Freeman LE, Lubin JH, Airola MS, Baris D, Ayotte JD, Taylor A, Paulu C, Karagas MR, Colt J, Ward MH, Huang AT, Bress W, Cherala S, Silverman DT, Cantor KP.

Environ Health Perspect. 2011 Sep;119(9):1279-85. doi: 10.1289/ehp.1002345. Epub 2011 Mar 21. Erratum in: Environ Health Perspect. 2011 Dec;119(12):A509.

20.

A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire.

Lesseur C, Gilbert-Diamond D, Andrew AS, Ekstrom RM, Li Z, Kelsey KT, Marsit CJ, Karagas MR.

Toxicol Lett. 2012 Apr 5;210(1):100-6. doi: 10.1016/j.toxlet.2012.01.015. Epub 2012 Jan 28.

Supplemental Content

Support Center